PANTHERX® RARE PHARMACY: Selected by Ultragenyx Pharmaceutical to Distribute DOJOLVI™ (triheptanoin), for Patients with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

PANTHERx® Rare Pharmacy announces that it has been selected by Ultragenyx Pharmaceutical as a limited distribution partner for new drug DOJOLVI™ (triheptanoin). DOJOLVI™ (a highly purified, pharmaceutical-grade, synthetic seven carbon fatty acid triglyceride) is a specially designed synthetic triglyceride compound, which was developed to treat patients with long-chain fatty acid oxidation disorders (LC-FAOD). Read More »

ARIDIS PHARMACEUTICALS: To Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced that Vu Truong, Ph.D., Chief Executive Officer, will participate in Cantor Fitzgerald's Virtual Symposium: "Winning Ways to Treat Infections and COVID-19" being held on Tuesday, June 30, 2020. Read More »

APHA: Joint Statement of the American Medical Association, American Pharmacists Association, and American Society of Health-System Pharmacists on new FDA action to Remove Emergency Use Authorization of Medications to Treat COVID-19

The American Medical Association, American Pharmacists Association, and American Society of Health-System Pharmacists appreciates the Food and Drug Administration's (FDA's) continuing efforts to review and advise the nation on the safe and effective use of hydroxychloroquine, chloroquine, and other medications to prevent and treat coronavirus. Read More »